The Food and Drug Administration Monday authorized the emergency use of the BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2.

The test is the second antigen diagnostic to earn an emergency use authorization from FDA and can be used in patient care settings approved for CLIA high or moderate complexity or waived testing.

However, the test’s emergency use is limited to authorized laboratories using the BD Veritor Plus Analyzer Instrument.

Related News Articles

Headline
The National Institutes of Health today announced clinical trials to investigate the safety and efficacy of a synthetic antibody therapy in COVID-19 patients.…
Headline
The Centers for Medicare & Medicaid Services will allow health insurers to offer premium reductions for individuals with 2020 coverage in the individual…
Headline
The Department of Health and Human Services Friday updated its guidance and FAQs  regarding the agency’s request for daily COVID-19-related hospital data…
Headline
The Centers for Disease Control and Prevention Aug. 3 at 3 p.m. ET will hold a webinar with updates on the COVID-19 response, including new resources for…
Headline
A study released today by the Centers for Disease Control and Prevention demonstrates that SARS-CoV-2 spreads efficiently in youth-centric settings,…
Headline
The Food and Drug Administration yesterday updated its FAQs on the emergency use authorization of remdesivir for use on certain hospitalized COVID-19 patients…